Skip to main content
Premium Trial:

Request an Annual Quote

Rules-Based Medicine Gets Award to Develop Cancer Biomarker Assays

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rules-Based Medicine today said it has received an award for about $3 million to fund the research and development of more than double the number of cancer-associated biomarker assays in its new OncologyMap product.

The funding is a Company Commercialization Award from the Cancer Prevention and Research Institute of Texas and will go toward a three-year plan to develop and validate multiplexed immunoassays that measure 150 to 180 blood-based biomarkers that the National Cancer Institute believes may be associated with cancer, RBM said in a statement. As a result of the work being carried out with the award, the firm believes the resulting product will include the largest number of quantitative immunoassays available for discovering and validating new diagnostic, prognostic, and companion diagnostic tests for cancer.

Austin, Texas-based RBM said in a statement that its Multi Analyte Profiling technology offers researchers "broad, cost-effective" protein analyses in multiples species from a small sample volume.

The company filed a registration statement with the US Securities Exchange Commission for an initial public offering of its common stock in December.